Leaders, not CEOs

Last week's $33 million series C round is expected to get cancer mAb company Igenica Inc. into the clinic, 5AM Ventures' John Diekman told BioCentury.

The company is running IND-enabling studies for a couple of candidates, with more coming up in the pipeline...